Is ARKG a Good Investment? The Case For and Against (2026)

The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from Cathie Wood's ARK Invest that targets companies it believes will benefit from advances in genomics, gene editing, molecular diagnostics, and biotechnology. The portfolio is highly concentrated, typically holding around 30 to 35 names, with the top 10 positions making up roughly 60% of assets as of early 2026. It tilts heavily toward early-stage, pre-profit and clinical-stage biotech names, including CRISPR gene-editing companies, molecular-diagnostics firms, and AI-driven drug discovery platforms. ARKG carries a 0.75% expense ratio and has seen its assets fall sharply from a peak near $9 billion in early 2021 to roughly $1.2 billion in early 2026, reflecting both outflows and a deep drawdown in speculative biotech.

Largest holdings (approximate as of early 2026; verify on ARK Invest's fund page):

ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like CRISPR Therapeutics, Tempus AI, Twist Bioscience, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly 60% of assets. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion. It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.

In its favour: it gives you Actively managed (no index); focused on genomics and biotech innovation exposure in one ticker at a 0.75% expense ratio, which is simple to hold and cheap to own.

• Cost vs alternatives: 0.75% is the fee; compare it to funds tracking a similar index.
• Concentration: check how much of ARKG sits in its largest holdings (TWST, TEM, TXG).
• Overlap: if you already own a broad-market fund, you may already hold much of this.
• Tracking scope: ARKG only gives you Actively managed (no index); focused on genomics and biotech innovation; it will not capture what sits outside that index.

“Diversified” is the word every index fund uses and it hides a wide range. The number that actually matters is how much of the fund sits in its largest positions, because that is the part that drives the return. In ARKG, the three largest positions are about 23.7% of the fund and the 10 largest are about 59.2%, with the single biggest at roughly 9.2%. Those are approximate weights as of early 2026, and because this is the published top 10 rather than the full book, treat 59.2% as a floor on concentration rather than the whole picture. Verify with ARK Invest.

That is a moderately concentrated fund. The largest names matter to the outcome without dominating it, which is typical of a broad market-cap-weighted index and is the shape most core holdings have.

This is also the number that decides whether ARKG adds diversification to your portfolio rather than to a portfolio in the abstract. A fund can be well spread on its own and still concentrate you further, if its largest holdings are names you already own directly or through another fund. That is a question about your account rather than about ARKG, and it is the one worth answering before you buy.

A fund is defined as much by what it leaves out as by what it holds, and the exclusions are rarely on the marketing page. ARKG tracks Actively managed (no index); focused on genomics and biotech innovation, so anything outside that index is simply absent from your portfolio no matter how much of the fund you own.

In practice that means checking three gaps. Whether the geography you want is covered, since a US index holds no international companies and a developed-markets index holds no emerging ones. Whether the size band you want is covered, because a large-cap index excludes the smaller companies some investors specifically want exposure to. And whether the asset class you want is covered at all, since an equity fund holds no bonds and gives you nothing to rebalance against in a drawdown.

None of these are faults. They are the fund doing exactly what it says. The mistake is assuming that owning a diversified fund means being diversified, when it means being diversified within one index.

Being specific about this is more useful than another paragraph on why it might be right.

• You already own most of it. If a broad-market fund you hold already contains TWST, TEM, TXG at meaningful weight, adding ARKG mostly increases your exposure to the same companies while adding a second fee. That is the single most common way people accidentally concentrate.
• You want the exposure for a short horizon. An index fund is a way to own an asset class over years. Over months it is simply the index, with all of the index's volatility and none of the compounding that makes holding it worthwhile.
• You need income you can rely on. Distributions from an equity index fund vary with what the underlying companies pay, so they are not a schedule you can plan around the way a bond ladder is.
• A cheaper fund tracks the same thing. Where two funds follow a similar index, the difference in expense ratio is one of the few advantages available to you without taking extra risk. Compare before assuming 0.75% is competitive.

The useful question is rarely “will ARKG go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how ARKG would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.

The bottom line: ARKG is a low-cost core building block for Actively managed (no index); focused on genomics and biotech innovation exposure, not a tactical bet on a single name. If you want Actively managed (no index); focused on genomics and biotech innovation exposure and the 0.75% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.

• What is ARKG? (holdings, cost, performance, and the themes it covers)
• ARKG dividend: yield and schedule